EXtension of Tablo TrEatmeNt Duration Registry
Completed
- Conditions
- Acute Kidney InjuryEnd Stage Renal Disease (ESRD)End Stage Renal Disease on Dialysis
- Interventions
- Device: Tablo Hemodialysis System
- Registration Number
- NCT04912050
- Lead Sponsor
- Outset Medical
- Brief Summary
Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- Participant weighs ≥ 34kg.
- Participant is hospitalized and has dialysis dependent End-Stage Kidney Disease or Acute Kidney Injury and is prescribed renal replacement therapy > 12 hours.
Exclusion Criteria
- Any documented condition that the Physician feels would prevent the participant from successful inclusion in the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Tablo Hemodialysis System Tablo Hemodialysis System Hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours on the Tablo Hemodialysis System
- Primary Outcome Measures
Name Time Method Treatment Success Up to 24 hours Percentage of treatments achieving prescribed dialysis treatment time ≤ 10%
- Secondary Outcome Measures
Name Time Method Tablo Cartridge Life up to 24 hours Measure the average number of cartridge changes required to complete a Tablo XT Treatment
Trial Locations
- Locations (1)
St. Mark's Hospital
🇺🇸Salt Lake City, Utah, United States